|
مقاله
|
Abstract
|
|
|
|
Title:
|
ormulation, Optimization and characterization of liposome-encapsulated Avastin®
|
|
Author(s):
|
Maryam Malakouti -Nejad, Dina Morshedi* Hasan Bardania, Farhang Aliakbari, Ali Reza Baradarn-Rafiei, Elahe Elahi,
|
|
Presentation Type:
|
Poster
|
|
Subject:
|
Cornea & lens
|
|
Others:
|
|
|
Presenting Author:
|
|
|
Name:
|
Maryam Malakouti Nejad
|
|
Affiliation :(optional)
|
Bioprocess Engineering Department, Institute of Industrial and Environmental Biotechnology, National Institute of Genetic Engineering and Biotechnology, Tehran, Iran
|
|
E mail:
|
sequence3130@yahoo.com
|
|
Phone:
|
00982188639775
|
|
Mobile:
|
09126132561
|
|
|
|
|
Purpose:
|
Bevacizumab, an anti-VEGF antibody is one of the most effective drugs widely used off label for treatment of ocular angiogenesis diseases. The aim of this study was to transport of Avastin using nanoliposomes as carrier and evaluatation of the effect of some independent variables including DPPC (1, 2-dipalmitoyl-sn-glycero-phosphocholine), cholesterol, and Avastin® concentrations and freeze/thawing cycles on drug entrapment efficiency % (DEE) utilizing response surface methodology (RSM).
|
|
Methods:
|
Optimal conditions for the maximum DEE (39.9%) was obtained with 1.6 mg Avastin®, 2 mg DPPC, 0.37mg cholesterol and 7 freeze/thawing cycles. Afterward the prepared nanoliposome – Avastin® (NLP-AVA) was characterized through the analysis of its particle size, zeta potential, and image. Moreover using MTT and LDH assays the safety of NLP-AVA was assessed.
|
|
Results:
|
Physical and chemical analysis indicated that the process of entrapment process of Avastin® into nanoliposome preserved the protein in native form.
|
|
Conclusion:
|
So entrapped Avastin® as the optimized NLP-AVA formulation meaningfully remains it safe, stable and functional for ocular drug delivery.
|
|
Attachment:
|
79Malakouti-Nejad.pptx
|
|